Deferoxamine and Deferiprone Combination Chelation Therapy with Blood Transfusion Support

The combination of deferoxamine and deferiprone with blood transfusion is a therapeutic approach used primarily in transfusion-dependent thalassemia patients to manage iron overload. This is not a single drug product but rather a combination therapy protocol involving two iron chelators and regular blood transfusions. Deferoxamine (also called desferrioxamine) is administered subcutaneously or intravenously, while deferiprone is an oral iron chelator. Both medications are used alongside regular blood transfusions to prevent and treat iron overload in patients with transfusion-dependent anemias, particularly beta-thalassemia. ## Mechanism and Efficacy The combination of deferoxamine and deferiprone has shown additive or synergistic effects in iron chelation. Studies have demonstrated that this combination can place patients into negative iron balance, meaning more iron is removed than accumulated. This is particularly important for patients who don't respond adequately to monotherapy with either agent. When administered with blood transfusions, intravenous deferoxamine has been shown to decrease serum ferritin levels significantly. The timing of administration is important - deferoxamine can be given during blood transfusion sessions, improving patient compliance and treatment efficacy. ## Clinical Applications This combination therapy is particularly valuable for: - Patients with severe iron overload who don't respond adequately to single-agent therapy - Patients with cardiac iron overload or cardiomyopathy - Cases where maximum chelation is required For patients with iron-induced cardiomyopathy or severe cardiac iron loading (T2* <20 ms), maximum chelation with 24-hour deferoxamine therapy in combination with deferiprone is recommended. ## Administration and Dosing Various administration protocols have been studied: - Deferoxamine can be administered subcutaneously for 8-24 hours, 5-7 days per week - Deferiprone is typically given orally three times daily - Intravenous deferoxamine can be administered during monthly blood transfusions - Some protocols involve daily deferiprone with subcutaneous deferoxamine on 2-6 days each week Dosing may include: - Deferoxamine: 40-60 mg/kg/day - Deferiprone: 75-100 mg/kg/day divided into three doses. ## Safety and Monitoring This combination therapy requires careful monitoring of: - Serum ferritin levels - Liver and cardiac iron by MRI T2* - Complete blood counts (particularly for neutropenia with deferiprone) - Renal and hepatic function - Auditory and visual function (for deferoxamine toxicity) The combination has been studied extensively and appears to be well-tolerated, with no significant increase in adverse effects compared to monotherapy with either agent. The search results also mention ongoing research into triple combination therapy with deferoxamine, deferiprone, and deferasirox for patients with very high iron overload, suggesting that combination approaches continue to evolve for managing severe transfusional iron overload.